You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 299 No. 10, March 12, 2008 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Commentary
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (1)
 •Contact me when this article is cited
 Related Content
 •Related letters
 •Similar articles in JAMA
 Topic Collections
 •Exercise
 •Obesity
 •Diabetes Mellitus
 •Nutritional and Metabolic Disorders, Other
 •Diet
 •Alert me on articles by topic

Reinventing Type 2 Diabetes

Pathogenesis, Treatment, and Prevention

Roger H. Unger, MD

JAMA. 2008;299(10):1185-1187.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The conventional glucocentric perspective of type 2 diabetes views hyperglycemia as a primary disease caused by an etiologically uncertain combination of obesity-associated insulin resistance and beta cell loss (a disease of glucose metabolism to be treated with antihyperglycemic agents, including high-dose insulin, if necessary). By contrast, the novel lipocentric view depicts the hyperglycemia of type 2 diabetes, and the underlying insulin resistance and beta cell loss, as being secondary to the metabolic trauma caused by ectopic lipid deposition or lipotoxicity.1 If this is in fact the case, hyperglycemia should be corrected by eliminating the lipid overload. The study by Dixon et al2 provides support for this lipocentric hypothesis, by demonstrating that weight loss that follows gastric banding is accompanied by remission of diabetes in 73% of obese patients with type 2 diabetes. This finding supports 45 years of biochemical, physiological, and clinical research pointing to lipid . . . [Full Text of this Article]

History of the Lipocentric Concept

Author Affiliations: Touchstone Center for Diabetes Research, University of Texas Southwestern Medical Center, and Veterans Affairs Medical Center, Dallas, Texas.


RELATED LETTERS

Insulin Therapy and Lipid Overload in Type 2 Diabetes
Paresh Dandona, Ajay Chaudhuri, and Husam Ghanim
JAMA. 2008;300(7):788-789.
EXTRACT | FULL TEXT  

Insulin Therapy and Lipid Overload in Type 2 Diabetes
Raffaele Marfella, Michelangela Barbieri, and Giuseppe Paolisso
JAMA. 2008;300(7):789.
EXTRACT | FULL TEXT  

Insulin Therapy and Lipid Overload in Type 2 Diabetes—Reply
Roger H. Unger
JAMA. 2008;300(7):790.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Insulin Therapy and Lipid Overload in Type 2 Diabetes
Marfella et al.
JAMA 2008;300:789-789.
FULL TEXT  

Insulin Therapy and Lipid Overload in Type 2 Diabetes
Dandona et al.
JAMA 2008;300:788-789.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.